Abstract
We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in 4 months after the withdrawal of everolimus and treatment with corticosteroids. Half dose (5 mg/day) of everolimus was rechallenged for 9 months until another grade 3 ILD developed. Everolimus kept the disease under control for 13 months including the discontinuation period.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects*
-
Carcinoma, Renal Cell / secondary*
-
Carcinoma, Renal Cell / therapy*
-
Enzyme Inhibitors / administration & dosage*
-
Enzyme Inhibitors / adverse effects*
-
Everolimus
-
Fatal Outcome
-
Humans
-
Kidney Neoplasms / secondary*
-
Kidney Neoplasms / therapy*
-
Lung Diseases, Interstitial / chemically induced*
-
Lung Diseases, Interstitial / drug therapy
-
Male
-
Prednisolone / administration & dosage
-
Severity of Illness Index
-
Sirolimus / administration & dosage
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives*
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Everolimus
-
Prednisolone
-
TOR Serine-Threonine Kinases
-
Sirolimus